Anti-CLDN18.2 antibodies and diagnostic uses thereof
AssigneeSuzhou Transcenta Therapeutics Co., Ltd.
InventorsXueming Qian, Xinlai Yao, Huanhuan Guo, Hongjun Li, Yi Gu
Life of this patent
Estimating the term…
Abstract
The present disclosure provides herein novel monoclonal anti-CLDN18.2 antibodies or antigen-binding fragments thereof which specifically recognize CLDN18.2 without cross-reacting with CLDN18.1. The present disclosure further provides isolated polynucleotides encoding such anti-CLDN18.2 antibodies or antigen-binding fragments thereof, vectors comprising such isolated polynucleotides, host cells comprising such vectors, pharmaceutical compositions and kits comprising such anti-CLDN18.2 antibodies or antigen-binding fragments thereof, and the diagnostic uses thereof.
Claims21
An isolated antibody or an antigen binding fragment thereof that specifically bind to CLDN18.2, comprising:
- a) a heavy chain CDR1 comprising the amino acid sequence of X1X2YX3H (SEQ ID NO:
- 8), a heavy chain CDR2 comprising the amino acid sequence of WIYPX4GX5X6X7X8YX9EKFKG (SEQ ID NO:
- 12), and a heavy chain CDR3 comprising the amino acid sequence of NYX10STFGY (SEQ ID NO:
- 24);
- and
- b) a light chain CDR1 comprising the amino acid sequence of RSSQNIVHSNGNTYLE (SEQ ID NO:
- 2), a light chain CDR2 comprising the amino acid sequence of KX11SNRFS (SEQ ID NO:
- 25), and a light chain CDR3 comprising the amino acid sequence of FQGSHVPFT (SEQ ID NO:
- 6);
- wherein X1 is R or T, X2 is N or Y, X3 is F or I, X4 is G or R, X5 is F or G, X6 is D or N, X7 is I or T, X8 is E or V, X9 is S or N, X10 is G or R, and X11 is V or I,
- and wherein the antibody or antigen binding fragment thereof comprises:
- a) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
- 1, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
- 3, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
- 5, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
- 2, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
- 4, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
- 6;
- or
- b) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
- 7, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
- 9, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
- 11, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
- 2, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
- 10, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
- 6.
Dependencies are inferred from the claim text.